It has chondrostimulating, regenerating, anti-inflammatory and analgesic effects. Chondroitin sulfate is involved in the construction of the basic substance of cartilage and bone tissue. Has chondroprotective properties; enhances metabolic processes in hyaline and fibrous cartilage and subchondral bone; inhibits the activity of enzymes that cause degradation (destruction) of articular cartilage; stimulates the production of proteoglycans by chondrocytes; influences phosphorus-calcium metabolism in cartilage tissue, stimulates its regeneration; participates in the construction of the basic substance of bone and cartilage tissue. It has anti-inflammatory and analgesic properties, helps reduce the release of inflammatory mediators and pain factors into the synovial fluid through synoviocytes and macrophages of the synovial membrane, and suppresses the secretion of leukotrienes and prostaglandins. The drug prevents connective tissue degeneration and reduces calcium loss, accelerating bone tissue restoration processes.
Chondroitin sulfate slows the progression of osteoarthritis and osteochondrosis. Promotes the restoration of the joint capsule and cartilaginous surfaces of the joints, prevents the collapse of connective tissue, and normalizes the production of joint fluid.
The clinical effect is manifested by an improvement in joint mobility and a decrease in pain intensity, while the therapeutic effect persists for a long time after the end of the course of therapy. When treating degenerative changes in joints accompanied by secondary synovitis, the effect is observed within 2-3 weeks from the start of the course.
Possessing structural similarity to heparin, it can potentially prevent the formation of fibrin thrombi in the synovial and subchondral microvasculature.